Semaglutide is a GLP-1 receptor agonist that mimics a gut hormone released after eating. It can reduce appetite and slow gastric emptying. Your dose is set and adjusted by a licensed provider, only if treatment is appropriate.
GLP-1 receptor agonist: a single incretin pathway.
Published evidence
In STEP 1, brand semaglutide 2.4 mg weekly produced mean weight loss of 14.9% at 68 weeks vs 2.4% placebo. Those averages describe the studied brand regimen, not compounded therapy. Individual results vary.
How it’s used here
Once weekly, titrated by your provider. Compounded after a valid prescription.
Prescribed, not sold
A licensed provider authorizes treatment only if it is medically appropriate, never as a cart-only purchase.
Titrated to you
Dosing is increased gradually under clinical guidance so your body can adjust. Your exact schedule is set by your provider.
Supported after
Dose adjustments and provider messaging are included so the plan can change with your response.
What to expect
1
Early weeks
Getting started
You typically begin at a low dose so your body can adjust. Many people notice appetite changes early on; others take longer. Side effects, if they occur, are often GI-related and may ease as titration continues.
2
Titration period
Building tolerance
Your provider may step the dose up on a schedule that fits you. Weight change, when it occurs, is gradual. Habits, starting weight, and adherence all matter. Individual results vary.
3
Maintenance
Finding your dose
You may settle into a maintenance dose. Trial averages (such as STEP 1) describe research populations at specific brand doses, not a guarantee for compounded therapy or for any one person.
4
Ongoing
Reviewed and adjusted
Your provider can review response and refine the plan. This is ongoing clinical care, not a one-time ship-and-forget order.
Every semaglutide prescription is written by a US-licensed provider who has reviewed your history, and who can decline when treatment is not appropriate.
The DirectGLP standard
Compounded medications contain clinically studied active ingredients but are prepared for you by a state-licensed 503A pharmacy. They are not the same as FDA-approved brand products (for example Wegovy®) and are not FDA-approved finished drugs. Trial results apply to the studied brand regimens and populations.
Asked plainly
Brand-name semaglutide products are FDA-approved for specific indications. The medication DirectGLP dispenses is compounded by a state-licensed 503A pharmacy and is not an FDA-approved finished product.
When prescribed, semaglutide is typically injected once weekly under the skin (for example abdomen, thigh, or upper arm). Supplies and instructions are included. Technique questions can go to your care team.
In the STEP 1 trial, adults on semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight over 68 weeks versus 2.4% with placebo. That average is not a personal guarantee. Your result depends on dose, adherence, starting weight, lifestyle, and medical factors. Compounded products were not the study drug.
Because it is a prescription medication. A licensed provider must review your health history and decide it is appropriate before it can be dispensed. The assessment and provider review carry no charge unless you proceed after a prescription.
Before you begin
Not for everyone.
GLP-1 therapy isn't appropriate for every patient. A licensed provider screens for these during your assessment, so please share your full history.
Personal/family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy, planning pregnancy, or breastfeeding
History of pancreatitis or known allergy to the medication
GLP-1 receptor agonists carry a boxed warning regarding thyroid C-cell tumors observed in rodents; it is unknown whether they cause medullary thyroid carcinoma (MTC) in humans. They are contraindicated in patients with a personal or family history of MTC or MEN 2. These medications are compounded by state-licensed 503A pharmacies and are not FDA-approved finished products. This page is educational and is not medical advice. Eligibility is always determined by a licensed provider after reviewing your full history.
Prescription required
